CureVac is a German biotechnology company with over 20 years experience in messenger RNA (mRNA) technology, developing and optimizing this versatile molecule for medical purposes.

The focus of CureVac's proprietary technology is using the mRNA platform as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. To date CureVac has applied its mRNA platform to develop cancer therapies, antibody therapies, a Rabies vaccine etc.

Dr. Franz Werner-Haas, acting Chief Executive Officer and Chief Operating Officer, explained “We have been working on our mRNA platform for almost two decades and are leveraging our deep scientific understanding of the technology. With recurring positive results for Flu, RSV, Rabies and now our Coronavirus vaccine candidate, we have demonstrated the sustained performance of our mRNA platform. We are convinced that with our expertise and advanced technology we are well positioned to fight viral outbreaks such as the current one and that our approach may provide the best chance to protect many people from SARS-CoV-2 and other health threats.”

Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, added “It is remarkable that with both vaccine candidates - Rabies and Coronavirus - as well as with our Flu and RSV projects, we were able to achieve positive results at such a low dose. The outcomes demonstrate the potential of our mRNA technology platform to revolutionize the field of vaccines.”

To date CureVac has received financial support for its Coronavirus vaccine development from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation as well as from the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense.